GLP-1 Drugs Are Rewriting the Food and Pharma Industries
Obesity drugs moved from niche to blockbuster, and every adjacent industry is scrambling to adjust.
0 reactions · anonymous
Appetite as a target
GLP-1 receptor agonists cut weight by 15–20% on average, and the pipeline is stacking more mechanisms on top. The knock-on effects reach far beyond clinics: airline weight allowances, restaurant portions, junk-food taxes.
The open question is adherence — stopping the drug regains weight, which pressures manufacturers into lifetime-pricing debates.
Building incoffeed — a daily editorial on tech, AI, fintech and business. Co-founder & editor.
Discussion
0// No comments yet — be the first to start the discussion.
